Replies to post #606869 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

False. Dr. Liau stated there were only 29 left in the placebo after crossover

Failure to understand how clinical trials work.

Patients in these type trials almost always end up with subsequent therapies upon progression. That may include experimental drugs and even the treatment drug., Does not matter, it is analyzed per ITT.

That is 99 vs 233. And the 99 who were randomized to placebo did better.

Even if you believe the post hoc analysis is valid, why would anybody take DCVax-L after surgery if they live longer by not taking it then?

[rkawong66]

Does it really matter if placebo patients were compared? These types of out-of-context fabricated statements are only meant to dissuade superficial retail shareholders.

The JAMA article puts all of this nonsense to bed, and in combination with Checkpoint Inhibitors, DC-Vax L crushes it with OVERALL SURVIVAL of 50% of patients at the 10-year mark !!!!

exwannabe and others just have some ridiculous axe to grind and don't care about misleading folks.

Patients know, the FDA and NIH know (SPORE grants to UCLA), certainly MHRA/NICE know, the Brain Tumor Charity and numerous other cancer centers and their doctors know the promise of DC-Vax from $NWBO. The insiders at NVCR also know it.

Nobel Prize in medicine for Dr. Linda Liau !!!